BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19025975)

  • 1. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
    Montillo M; Tedeschi A; O'Brien S; Di Raimondo F; Lerner S; Ferrajoli A; Morra E; Keating MJ
    Cancer; 2003 Jan; 97(1):114-20. PubMed ID: 12491512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dmoszyńska A; Wojtaszko M; Skotnicki AB; Nowak W; Hellmann A; Lewandowski K; Zdziarska B; Konopka L; Ceglarek B; Dwilewicz-Trojaczek J; Boguradzki P; Kuliczkowski K; Sułek K; Warzocha K
    Med Sci Monit; 2005 Oct; 11(10):PI71-9. PubMed ID: 16192912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
    Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
    Laurencet FM; Zulian GB; Guetty-Alberto M; Iten PA; Betticher DC; Alberto P
    Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
    Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K;
    Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
    Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
    Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.